SAKK 21/12: a phase II trial of transdermal CR1447 in breast cancer patients.

Marcus VetterKarin M RothgiesserQiyu LiHanne HawleWolfgang SchönfeldKarin RibiSalome RinikerRoger von MoosAndreas TrojanElena KralidisMathias FehrAndreas MüllerBeat Thürlimannnull null

Published in: Endocrine oncology (Bristol, England) (2022)

Despite this trial being negative, the 24% DC24 rate in a second-line setting, and the prolonged partial response experienced by a patient, indicate activity. Further evaluation of CR1447 in endocrine-sensitive patients or combination trials appears warranted.

Keyphrases

end stage renal disease
ejection fraction
newly diagnosed
chronic kidney disease
clinical trial
peritoneal dialysis
case report
dendritic cells
open label
phase ii